Latest On Sino Biopharmaceutical Limited (SBMFF):
About Sino Biopharmaceutical Limited (SBMFF):
Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
General
- Name Sino Biopharmaceutical Limited
- Symbol SBMFF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 24,328
- Last Split Factor3:2
- Last Split Date2020-07-20
- Fiscal Year EndDecember
- Web URLhttp://www.sinobiopharm.com
Valuation
- Trailing PE 34.24
- Forward PE 45.45
- Price/Sales (Trailing 12 Mt.) 5.22
- Price/Book (Most Recent Quarter) 4.05
- Enterprise Value Revenue 0.81
- Enterprise Value EBITDA 3.38
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin 10%
- Return on Assets 4%
- Return on Equity 10%
- Earnings Per Share $0.03
- Revenue Per Share $0
- Gross Profit 19.31 billion
- Quarterly Earnings Growth -19.4%
ESG Rating
Highlights
- Market Capitalization 21.76 billion
- PEG Ratio 11.64
- Book Value Per Share $0.25
Share Statistics
- Shares Outstanding 18.86 billion
- Shares Float 8.9 billion
- % Held by Insiders 4749%
- % Held by Institutions 15.9%
Technicals
- Beta 0.56
- 52 Week High $1.45
- 52 Week Low $0.79
- 50 Day Moving Average 1.03
- 200 Day Moving Average 1.02
Dividends
- Forward Annual Dividend Rate $0.01
- Forward Annual Dividend Yield 0.91%
- Payout Ratio 18%
- Dividend Date 2017-12-15
- ExDividend Date 2020-12-11
- Dividend Per Share $0.01
- Dividend Yield 0%
Sino Biopharmaceutical Limited (SBMFF) Dividend Calendar:
SBMFF's last dividend payment was made to shareholders on December 15, 2017.
Sino Biopharmaceutical Limited pays out 18% of its earnings out as a dividend.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Sino Biopharmaceutical Limited (SBMFF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-09-30 | 2020-11-30 | $N/A | $0.03 | $0.05 | -40% |
2020-06-30 | 2020-09-30 | $N/A | $0.01 | $0.04 | -87.5% |
2020-03-31 | 2020-06-30 | $N/A | $0.00 | $0.04 | -93.5% |
2019-12-31 | 2020-03-31 | $N/A | $0.01 | $0.05 | -87.2% |
2019-09-30 | 2019-12-31 | $6.79 billion | $0.00 | $0.04 | -91.25% |
2019-06-30 | 2019-09-30 | $6.32 billion | $0.01 | $0.04 | -85% |
2019-03-31 | 2019-06-30 | $6.21 billion | $0.00 | $0.05 | -91% |
2018-12-31 | 2019-03-31 | $5.16 billion | $0.01 | $0.04 | -83% |
2018-09-30 | 2018-12-31 | $6 billion | $0.05 | $0.05 | 8.4% |
2018-06-30 | 2018-09-30 | $3.85 billion | $0.01 | $0.04 | -84% |
2018-03-31 | 2018-06-30 | $4.65 billion | $0.00 | $0.07 | -93.29% |
2017-12-31 | 2018-03-31 | $3.37 billion | $0.01 | $0.04 | -83% |
2017-09-30 | 2017-12-31 | $4.65 billion | $0.00 | $0.05 | -92.2% |
2017-06-30 | 2017-09-30 | $3.62 billion | $0.01 | $0.04 | -84.75% |
2017-03-31 | 2017-06-30 | $3.86 billion | $0.00 | $0.05 | -91.6% |
2016-12-31 | 2017-03-31 | $3.5 billion | $0.01 | $0.04 | -87.5% |
2016-09-30 | 2016-12-31 | $0.00 | $0.04 | -94.75% | |
2016-06-30 | 2016-09-30 | $0.00 | $0.03 | -86% | |
2016-03-31 | 2016-06-30 | $0.00 | $0.06 | -93.33% | |
2015-12-31 | 2016-03-31 | $0.00 | $0.05 | -92% | |
2015-09-30 | 2015-12-31 | $0.00 | $0.07 | -95.71% | |
2015-06-30 | 2015-09-30 | $0.00 | $0.05 | -92.8% | |
2015-03-31 | 2015-06-30 | $0.00 | |||
2014-12-31 | 2015-03-31 | $0.00 | $0.04 | -92.25% | |
2014-09-30 | 2014-12-31 | $0.00 | $0.06 | -95.33% | |
2014-06-30 | 2014-09-30 | $0.00 | $0.04 | -89.75% | |
2014-03-31 | 2014-06-30 | $0.00 | |||
2013-12-31 | 2014-03-31 | $0.00 | |||
2013-09-30 | 2013-12-31 | $0.00 | |||
2013-06-30 | 2013-09-30 | $0.00 | |||
2013-03-31 | 2013-06-30 | $0.00 | |||
2012-12-31 | 2013-03-31 | $0.00 | |||
2012-09-30 | 2012-12-31 | $0.00 | |||
2012-06-30 | 2012-09-30 | $0.00 | |||
2012-03-31 | 2012-06-30 | $0.00 | |||
2011-12-31 | 2012-03-31 | $0.00 | |||
2011-09-30 | 2011-12-31 | $0.00 | |||
2011-06-30 | 2011-09-30 | $0.00 | |||
2011-03-31 | 2011-06-30 | $0.00 | |||
2010-12-31 | 2011-03-31 | $0.00 | |||
2010-09-30 | 2010-12-31 | $0.00 | |||
2010-06-30 | 2010-06-30 | $0.00 | |||
2010-03-31 | 2010-03-31 | $0.00 |
Sino Biopharmaceutical Limited (SBMFF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Research Development | N/A | N/A | N/A | N/A | N/A |
Income Before Tax | N/A | N/A | N/A | N/A | 1.85 billion |
Selling General Administrative | N/A | N/A | N/A | N/A | 3.34 billion |
Gross Profit | N/A | N/A | N/A | N/A | 5.47 billion |
Ebit | N/A | N/A | N/A | N/A | 1.7 billion |
Operating Income | N/A | N/A | N/A | N/A | 1.7 billion |
Income Tax Expense | 239.8 million | 325.64 million | 212.25 million | 57.19 million | 382.61 million |
Total Revenue | N/A | N/A | N/A | N/A | 6.79 billion |
Cost of Revenue | N/A | N/A | N/A | N/A | 1.32 billion |
Total Other Income Expense Net | N/A | N/A | N/A | N/A | 149.3 million |
Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 1.47 billion |
Net Income Applicable to Common Shares | 637.42 million | 351.06 million | 862.02 million | 451.28 million | 811.17 million |
Balance Sheet:
Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
---|---|---|---|---|---|
Total Liabailities | N/A | N/A | N/A | N/A | 14.64 billion |
Total Stockholder Equity | N/A | N/A | N/A | N/A | 30.58 billion |
Other Current Liabilities | 7 billion | N/A | N/A | N/A | 6.92 billion |
Total Assets | N/A | N/A | N/A | N/A | 53.77 billion |
Common Stock | 416.14 million | 278.3 million | 278.32 million | 278.45 million | 278.45 million |
Other Current Assets | N/A | N/A | N/A | N/A | N/A |
Retained Earnings | N/A | N/A | N/A | N/A | N/A |
Other Liabilities | 1.86 billion | 1.89 billion | 1.87 billion | 1.97 billion | 2 billion |
Other Assets | 1.53 billion | 1.59 billion | 1.66 billion | 2.28 billion | 2.4 billion |
Cash | N/A | N/A | N/A | N/A | 6.14 billion |
Total Current Liabilities | 9.94 billion | N/A | N/A | N/A | 10.09 billion |
Other Stockholder Equity | 31.67 billion | 31.65 billion | 31.84 billion | 31.25 billion | 30.74 billion |
Property, Plant & Equipment | 8.66 billion | 8.57 billion | 8.34 billion | 8.21 billion | 6.53 billion |
Total Current Assets | 30.4 billion | N/A | N/A | N/A | 21.86 billion |
Long Term Investments | N/A | N/A | N/A | N/A | 1.21 billion |
Net Tangible Assets | 10.47 billion | 10.18 billion | 10.3 billion | 10.23 billion | 8.8 billion |
Short Term Investments | N/A | N/A | N/A | N/A | N/A |
Long Term Debt | N/A | N/A | N/A | N/A | 2.48 billion |
Inventory | 1.76 billion | N/A | N/A | N/A | 1.59 billion |
Accounts Payable | 2.36 billion | N/A | N/A | N/A | 2.37 billion |
Sino Biopharmaceutical Limited (SBMFF) Chart:
Sino Biopharmaceutical Limited (SBMFF) News:
Below you will find a list of latest news for Sino Biopharmaceutical Limited (SBMFF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sino Biopharmaceutical Limited (SBMFF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Sino Biopharmaceutical Limited (SBMFF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-01-24 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000101915520000020/0001019155-20-000020-index.htm |
2014-04-08 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380514000751/0001193805-14-000751-index.htm |
2016-05-25 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380516003321/0001193805-16-003321-index.htm |
2016-09-13 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380516003943/0001193805-16-003943-index.htm |
2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1604982/000119380517002605/0001193805-17-002605-index.htm |
2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1604982/000119380519001656/0001193805-19-001656-index.htm |